Deca-Durabolin Orgaject

Šalis: Naujoji Zelandija

kalba: anglų

Šaltinis: Medsafe (Medicines Safety Authority)

Veiklioji medžiaga:

Nandrolone decanoate 25 mg/mL

Prieinama:

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics

INN (Tarptautinis Pavadinimas):

Nandrolone decanoate 25 mg/mL

Dozė:

25 mg/mL

Vaisto forma:

Solution for injection

Sudėtis:

Active: Nandrolone decanoate 25 mg/mL Excipient: Arachis oil Benzyl alcohol

Vienetai pakuotėje:

Syringe, Orgaject, disposible 1 mL, 1 mL

Klasė:

Prescription

Recepto tipas:

Prescription

Pagaminta:

Aspen Oss B.V

Terapinės indikacijos:

DECA-DURABOLIN can be used for the treatment of osteoporosis; for the palliative treatment of selected cases of disseminated mammary carcinoma in women and as an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance.

Produkto santrauka:

Package - Contents - Shelf Life: Syringe, Orgaject, disposible 1 mL - 1 mL - 36 months from date of manufacture stored at or below 25°C

Leidimo data:

1969-12-31

Prekės savybės

NEW ZEALAND DATA SHEET 
Deca-Durabolin D130424 Version 3.1 

Page1 
DECA-DURABOLIN

PRESENTATION 
Each pre-filled syringe contains 1 mL of 25
mg/ mL nandrolone decanoate. 
Each pre-filled syringe contains 1 mL of 50 mg/ mL
nandrolone decanoate. 
Each pre-filled syringe is affixed with a needle 
CLOSED BY A NEEDLE SHIELD OF NATURAL RUBBER LATEX 
(See warnings and precautions for use). 
Each ampoule contains 1 ml of 50 mg/ml nandrolone decanoate. 

Each ml of the yellow, oily solution contains: 
25 or 50 mg nandrolone decanoate. 

USES 

ACTIONS 
DECA-DURABOLIN is an injectable anabolic preparation.  The
pharmacologically active substance is 
nandrolone.  The decanoate ester gives the preparation a
duration of action of about three weeks after 
injection. 
Nandrolone is chemically related to the male hormone.  Compared
to testosterone, it has an enhanced 
anabolic and a reduced androgenic activity. 
This has been demonstrated in animal bioassays and 
explained by receptor binding studies. 
The low androgenicity of nandrolone is confirmed in clinical 
use. 
In the human, DECA-DURABOLIN has been shown to
positively influence calcium metabolism and to 
increase bone mass in osteoporosis.  In women with disseminated
mammary carcinoma, DECA-
DURABOLIN has been reported to produce objective
regressions for many months.  Furthermore, 
DECA-DURABOLIN has a nitrogen-saving action. 
This effect on protein metabolism has been established
by metabolic studies and is utilized 
therapeutically in conditions where
a protein deficiency exists such as during
chronic debilitating 
diseases and after major surgery and severe trauma.  In these
conditions, DECA-DURABOLIN serves 
as a supportive adjunct to
specific therapies and dietary measures as well as parenteral nutrition. 
Androgenic effects (e.g. virilisation) are relatively uncommon
at